We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …

We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …

This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the
safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic …

Background Inhaled antibacterial agents are used to manage chronic pulmonary infections
in cystic fibrosis (CF) and non-CF bronchiectasis. However, established nebulized …

Background The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas
aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical …

Bronchiectasis is a chronic respiratory disease with heterogeneous etiology, characterized
by a cycle of bacterial infection and inflammation, resulting in increasing airway damage …

Background In patients with non-cystic fibrosis bronchiectasis, lung infection with
Pseudomonas aeruginosa is associated with frequent pulmonary exacerbations and …

There are strong data supporting using the use of aerosolized antibiotics for the treatment of
Gram-negative infections in patients with cystic fibrosis (CF). The regular use of aerosol …

We conducted a meta-analysis of randomised trials to evaluate the efficacy and safety of
inhaled antibiotics in patients with stable non-cystic fibrosis (CF) bronchiectasis. We …

Abstract Background and Aims The evidence supported the use of nebulized antibiotics in
non‐cystic fibrosis (non‐CF) bronchiectasis is indefinite. A meta‐analysis was performed to …